• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转录组与孟德尔遗传综合分析揭示 CTLA-4 相关长链非编码 RNA 的新型预后生物标志物及氮代谢通路在肺腺癌发展中的保护作用。

Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development.

机构信息

Department of Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China.

Department of Radiation Oncology, Guangdong Second People's Hospital, Jinan University, Guangzhou, China.

出版信息

BMC Cancer. 2024 Aug 14;24(1):1009. doi: 10.1186/s12885-024-12777-7.

DOI:10.1186/s12885-024-12777-7
PMID:39143529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11323378/
Abstract

OBJECTIVE

Since in the cancer setting, tumor cells may use cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to evade the immune system. This study aimed to identify CTLA-4-related long non-coding RNAs (lncRNAs) and assess their roles in lung adenocarcinoma (LUAD) development.

METHODS

Clinical and genomic data were obtained from The Cancer Genome Atlas (TCGA), MSigDB and Gene Weaver. CTLA-4-related lncRNA-based gene signatures (CTLA4LncSigs) were identified using Cox regression, establishing a risk score model and an independent prognostic model. Enrichment analysis (GO/KEGG) was performed. Mendelian randomization (MR) analysis investigated the nitrogen metabolism and lung cancer relationship, with Bayesian weighted MR (BWMR) addressing uncertainties. Correlations with tumor microenvironment and drug sensitivity were explored.

RESULTS

Nineteen CTLA4LncSigs significantly influenced LUAD prognosis. The risk score demonstrated independence as a prognostic factor. Functional analysis revealed lncRNAs' impact on nitrogen metabolism. MR and BWMR confirmed the protective role of the nitrogen metabolism pathway in lung cancer.

CONCLUSION

Our study identifies CTLA-4-related lncRNAs associated with LUAD prognosis and uncovers a previously undiscovered protective role of the nitrogen metabolism pathway in combating LUAD development, providing new insights into potential therapeutic targets and prognostic biomarkers for this aggressive cancer subtype.

摘要

目的

由于在癌症环境中,肿瘤细胞可能利用细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4)来逃避免疫系统。本研究旨在鉴定 CTLA-4 相关的长非编码 RNA(lncRNA),并评估其在肺腺癌(LUAD)发展中的作用。

方法

从癌症基因组图谱(TCGA)、MSigDB 和 Gene Weaver 获得临床和基因组数据。使用 Cox 回归、建立风险评分模型和独立预后模型来识别 CTLA-4 相关 lncRNA 为基础的基因特征(CTLA4LncSigs)。进行富集分析(GO/KEGG)。孟德尔随机分析(MR)研究氮代谢与肺癌的关系,贝叶斯加权 MR(BWMR)解决不确定性。探索与肿瘤微环境和药物敏感性的相关性。

结果

19 个 CTLA4LncSigs 显著影响 LUAD 的预后。风险评分作为预后因素具有独立性。功能分析显示 lncRNA 对氮代谢的影响。MR 和 BWMR 证实了氮代谢途径在肺癌中的保护作用。

结论

本研究鉴定了与 LUAD 预后相关的 CTLA-4 相关 lncRNA,并揭示了氮代谢途径在对抗 LUAD 发展中的以前未被发现的保护作用,为这种侵袭性癌症亚型提供了新的潜在治疗靶点和预后生物标志物。

相似文献

1
Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development.转录组与孟德尔遗传综合分析揭示 CTLA-4 相关长链非编码 RNA 的新型预后生物标志物及氮代谢通路在肺腺癌发展中的保护作用。
BMC Cancer. 2024 Aug 14;24(1):1009. doi: 10.1186/s12885-024-12777-7.
2
Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.二硫键相关 lncRNAs 特征预测肺腺癌的预后和免疫治疗效果。
Aging (Albany NY). 2024 Jun 10;16(11):9972-9989. doi: 10.18632/aging.205911.
3
A methylation-related lncRNA-based prediction model in lung adenocarcinomas.基于甲基化相关长链非编码 RNA 的肺腺癌预测模型。
Clin Respir J. 2024 Aug;18(8):e13753. doi: 10.1111/crj.13753.
4
An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma.一个与外泌体相关的长链非编码 RNA 预后模型与肺腺癌的免疫微环境和治疗反应相关。
Clin Exp Med. 2024 May 18;24(1):104. doi: 10.1007/s10238-024-01319-x.
5
Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.鉴定和验证肺腺癌中一种新的氧化还原相关长非编码 RNA 预后标志物。
Bioengineered. 2021 Dec;12(1):4331-4348. doi: 10.1080/21655979.2021.1951522.
6
N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.N-6 甲基化相关长链非编码 RNA 是肺腺癌的潜在标志物,并影响肿瘤微环境。
J Clin Lab Anal. 2021 Nov;35(11):e23951. doi: 10.1002/jcla.23951. Epub 2021 Sep 24.
7
Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma.内质网应激相关长链非编码 RNA 预后特征分析及 RP11-295G20.2 敲低在肺腺癌中的抑瘤作用。
Sci Rep. 2024 May 29;14(1):12283. doi: 10.1038/s41598-024-62836-z.
8
Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.鉴定一个免疫相关的六个长非编码 RNA 特征作为肺腺癌的新型预后生物标志物。
Biosci Rep. 2021 Jan 29;41(1). doi: 10.1042/BSR20202444.
9
Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.独特的转移相关 lncRNA 特征可优化肺腺癌肿瘤复发预测。
Thorac Cancer. 2020 Mar;11(3):728-737. doi: 10.1111/1759-7714.13325. Epub 2020 Jan 28.
10
Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes.肺腺癌预后细胞死亡指数:基于十二种程序性细胞死亡模式基因的综合转录组分析。
Front Biosci (Landmark Ed). 2024 Apr 1;29(4):135. doi: 10.31083/j.fbl2904135.

本文引用的文献

1
2'-O-methylation at internal sites on mRNA promotes mRNA stability.mRNA 内部位点的 2'-O-甲基化促进 mRNA 的稳定性。
Mol Cell. 2024 Jun 20;84(12):2320-2336.e6. doi: 10.1016/j.molcel.2024.04.011.
2
RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response.RNA M6A 修饰塑造皮肤黑色素瘤肿瘤微环境并预测免疫治疗反应。
Pigment Cell Melanoma Res. 2024 Jul;37(4):496-509. doi: 10.1111/pcmr.13170. Epub 2024 Apr 16.
3
Identification and prognostic analysis of candidate biomarkers for lung metastasis in colorectal cancer.
结直肠癌肺转移相关候选生物标志物的鉴定与预后分析。
Medicine (Baltimore). 2024 Mar 15;103(11):e37484. doi: 10.1097/MD.0000000000037484.
4
Graphene therapy-related lncRNAs as prognostic and immune microenvironmental biomarkers in hepatocellular carcinoma.作为肝细胞癌预后和免疫微环境生物标志物的石墨烯治疗相关长链非编码RNA
Transl Oncol. 2024 May;43:101915. doi: 10.1016/j.tranon.2024.101915. Epub 2024 Feb 17.
5
Computational identification of long non-coding RNAs associated with graphene therapy in glioblastoma multiforme.多形性胶质母细胞瘤中与石墨烯疗法相关的长链非编码RNA的计算鉴定
Brain Commun. 2023 Oct 25;6(1):fcad293. doi: 10.1093/braincomms/fcad293. eCollection 2024.
6
A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.一种用于预测肺腺癌患者预后和筛选潜在治疗药物的铁死亡相关长链非编码RNA特征:一项回顾性研究。
Cancer Rep (Hoboken). 2024 Jan;7(1):e1925. doi: 10.1002/cnr2.1925. Epub 2023 Dec 3.
7
A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma.一种新型中性粒细胞胞外诱捕网相关长链非编码 RNA 标志物可预测早期肺腺癌患者的预后。
Ann Med. 2023;55(2):2279754. doi: 10.1080/07853890.2023.2279754. Epub 2023 Nov 19.
8
Leveraging a Genomic Instability-Derived Signature to Predict the Prognosis and Therapy Sensitivity of Clear Cell Renal Cell Carcinoma.利用基因组不稳定性衍生特征预测透明细胞肾细胞癌的预后和治疗敏感性
Clin Genitourin Cancer. 2024 Apr;22(2):134-148.e8. doi: 10.1016/j.clgc.2023.10.004. Epub 2023 Oct 11.
9
Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.全面评估碱基切除修复(BER)相关长链非编码 RNA 作为肺腺癌的预后和功能生物标志物:对个性化治疗和免疫调节的影响。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17199-17213. doi: 10.1007/s00432-023-05435-1. Epub 2023 Oct 3.
10
Improved prediction of prognosis and therapy response for lung adenocarcinoma after identification of DNA-directed RNA polymerase-associated lncRNAs.在鉴定出与DNA指导的RNA聚合酶相关的长链非编码RNA后,改善了肺腺癌预后和治疗反应的预测。
J Cancer Res Clin Oncol. 2023 Nov;149(14):12737-12754. doi: 10.1007/s00432-023-05118-x. Epub 2023 Jul 15.